Atopic dermatitis: understanding the disease and its management
- PMID: 17971284
- DOI: 10.1185/030079907X242593
Atopic dermatitis: understanding the disease and its management
Abstract
Objective: Atopic dermatitis (AD) is a common, chronic, inflammatory skin disease that can significantly reduce the quality of life of not only patients but also entire families. This review will focus on the currently available non-pharmacologic and pharmacologic treatments for the control and management of AD.
Research design and methods: A review of English-language articles from January 1953 to May 2006 was performed within the MEDLINE database. Search terms included, but were not limited to, atopic dermatitis, topical corticosteroids, and topical calcineurin inhibitors. Studies evaluating the diagnosis, physical and psychological burden, and underlying pathophysiology of AD were included. Particular focus was placed on literature presenting key safety and efficacy data from clinical trials involving AD treatment.
Results: Although good skin care and trigger avoidance are fundamental to AD management, most patients also require pharmacologic intervention. Topical therapies comprise the foundation of AD treatment. In particular, topical corticosteroids have been a mainstay in AD treatment for several decades and the newer topical calcineurin inhibitors have become a valuable addition to the therapeutic armamentarium. TCIs are a safe and effective AD treatment; they limit the number of disease flares, extend the time between flares, and provide a steroid-sparing option that may be of particular benefit in the pediatric population. The use of more potent therapies, such as systemic (oral/injected) agents or phototherapy, is typically limited to the treatment of severe, refractory disease. Additionally, owing to the increased risk for bacterial, viral, and fungal infections in patients with AD, topical or systemic antimicrobials are an important component of treatment.
Limitations: Case reports and small-scale studies were typically not included in this analysis and owing to the limited number of trials evaluating TCSs, consensus statements and comprehensive review articles were used to obtain information pertaining to the use of this treatment in AD.
Conclusions: AD is a common, chronic disease requiring a long-term management strategy that incorporates preventive measures and a multipronged treatment approach.
Similar articles
-
Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.Br J Dermatol. 2006 Apr;154(4):579-85. doi: 10.1111/j.1365-2133.2006.07157.x. Br J Dermatol. 2006. PMID: 16536797 Review.
-
Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.Clin Ther. 2006 Dec;28(12):1972-82. doi: 10.1016/j.clinthera.2006.12.014. Clin Ther. 2006. PMID: 17296454 Review.
-
Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption.Am J Ther. 2009 May-Jun;16(3):264-73. doi: 10.1097/MJT.0b013e31818a975c. Am J Ther. 2009. PMID: 19262357 Review.
-
Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis.Clin Pediatr (Phila). 2008 May;47(4):332-46. doi: 10.1177/0009922807309421. Epub 2007 Dec 5. Clin Pediatr (Phila). 2008. PMID: 18057146
-
[Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].Pol Merkur Lekarski. 2004;17 Suppl 3:3-15. Pol Merkur Lekarski. 2004. PMID: 15688665 Review. Polish.
Cited by
-
Therapeutic effects of fermented soycrud on phenotypes of atopic dermatitis induced by phthalic anhydride.Lab Anim Res. 2013 Jun;29(2):103-12. doi: 10.5625/lar.2013.29.2.103. Epub 2013 Jun 24. Lab Anim Res. 2013. PMID: 23825483 Free PMC article.
-
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response.J Allergy Clin Immunol. 2011 Sep;128(3):583-93.e1-4. doi: 10.1016/j.jaci.2011.05.042. Epub 2011 Jul 16. J Allergy Clin Immunol. 2011. PMID: 21762976 Free PMC article.
-
Introduction.Adv Exp Med Biol. 2024;1447:1-10. doi: 10.1007/978-3-031-54513-9_1. Adv Exp Med Biol. 2024. PMID: 38724779
-
Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis.Paediatr Drugs. 2009;11(6):407-26. doi: 10.2165/10481960-000000000-00000. Paediatr Drugs. 2009. PMID: 19877726 Review.
-
Immunomodulatory effects of Pseudostellaria heterophylla (Miquel) Pax on regulation of Th1/Th2 levels in mice with atopic dermatitis.Mol Med Rep. 2017 Feb;15(2):649-656. doi: 10.3892/mmr.2016.6093. Epub 2016 Dec 29. Mol Med Rep. 2017. PMID: 28035398 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources